Literature DB >> 2196148

Extravascular penetration of ciprofloxacin. A review.

T Bergan1.   

Abstract

The pharmacokinetics of ciprofloxacin after oral and intravenous administration have been studied extensively, and the results have been published worldwide. This paper serves as a review of the pharmacokinetics of ciprofloxacin, with specific reference to its penetration into body fluids and tissues. Ciprofloxacin has a protein binding of approximately 30% and penetrates well into tissues. For instance, the total concentration (area under the serum concentration-time curve) in peripheral human lymph is 70% of the serum values, and the peak level in lymph appears with 1-2 hr. The corresponding value for suction skin blisters is 60% and for inflammatory blisters 120%. Ciprofloxacin is concentrated in white blood cells, lung, prostate, and kidney and reaches concentrations above serum in many other tissues as well. Urine concentrations are up to 100 times those in serum. The levels in bile are comparable or only slightly higher (less than or equal to x 10) than serum levels. The penetration into cerebrospinal fluid (CSF) is low; the CSF levels are 4-10% of the serum levels in noninflammatory CSF and 30-50% in CSF from patients with meningitis.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2196148     DOI: 10.1016/0732-8893(90)90093-b

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN: 0732-8893            Impact factor:   2.803


  11 in total

Review 1.  Use of newer quinolones for the treatment of intraabdominal infections: focus on clinafloxacin.

Authors:  C E Nord
Journal:  Infection       Date:  1999 May-Jun       Impact factor: 3.553

2.  Transepithelial transport of the fluoroquinolone ciprofloxacin by human airway epithelial Calu-3 cells.

Authors:  M E Cavet; M West; N L Simmons
Journal:  Antimicrob Agents Chemother       Date:  1997-12       Impact factor: 5.191

Review 3.  Interethnic differences in pharmacokinetics of antibacterials.

Authors:  Danny Tsai; Janattul-Ain Jamal; Joshua S Davis; Jeffrey Lipman; Jason A Roberts
Journal:  Clin Pharmacokinet       Date:  2015-03       Impact factor: 6.447

4.  Screening rectal culture to identify fluoroquinolone-resistant organisms before transrectal prostate biopsy: do the culture results between office visit and biopsy correlate?

Authors:  Michael A Liss; Kristen K Nakamura; Rachel Meuleners; Surendra B Kolla; Atreya Dash; Ellena M Peterson
Journal:  Urology       Date:  2013-07       Impact factor: 2.649

5.  Ciprofloxacin treatment failure in a murine model of pyelonephritis due to an AAC(6')-Ib-cr-producing Escherichia coli strain susceptible to ciprofloxacin in vitro.

Authors:  T Guillard; E Cambau; F Chau; L Massias; C de Champs; B Fantin
Journal:  Antimicrob Agents Chemother       Date:  2013-09-09       Impact factor: 5.191

6.  Comparison of intravenous/oral ciprofloxacin plus metronidazole versus piperacillin/tazobactam in the treatment of complicated intraabdominal infections.

Authors:  S M Cohn; P A Lipsett; T G Buchman; W G Cheadle; J W Milsom; S O'Marro; A E Yellin; S Jungerwirth; E V Rochefort; D C Haverstock; S F Kowalsky
Journal:  Ann Surg       Date:  2000-08       Impact factor: 12.969

7.  Penetration of ciprofloxacin into the human pancreas.

Authors:  R Isenmann; H Friess; P Schlegel; K Fleischer; M W Büchler
Journal:  Infection       Date:  1994 Sep-Oct       Impact factor: 3.553

Review 8.  Ciprofloxacin extended release: in the treatment of urinary tract infections and uncomplicated pyelonephritis.

Authors:  John Waugh; Gillian M Keating
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923

9.  A case study of in silico modelling of ciprofloxacin hydrochloride/metallic compound interactions.

Authors:  Aleksandra Stojkovic; Jelena Parojcic; Zorica Djuric; Owen I Corrigan
Journal:  AAPS PharmSciTech       Date:  2013-12-05       Impact factor: 3.246

Review 10.  Ciprofloxacin. An updated review of its pharmacology, therapeutic efficacy and tolerability.

Authors:  R Davis; A Markham; J A Balfour
Journal:  Drugs       Date:  1996-06       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.